NCT07215741

Brief Summary

This is a retrospective, multi-center observational study to assess real-world outcomes of StimLabs human placental membrane tissue used in the treatment of hard-to-heal wounds, including chronic ulcers, diabetic foot ulcers (DFUs), and venous leg ulcers (VLUs). The collection of retrospective real-world data provides a broad range of experiences related to patient healthcare and treatment.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2025

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2025

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

September 25, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

October 10, 2025

Completed
22 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

October 10, 2025

Status Verified

September 1, 2025

Enrollment Period

2 months

First QC Date

September 25, 2025

Last Update Submit

October 8, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • The proportion of target ulcers achieving complete wound closure during the observational period

    Determine the percent (%) of target ulcers achieving complete wound closure at 12 weeks.

    1-12 weeks

Secondary Outcomes (3)

  • Percent area reduction

    1-12 weeks

  • Time to closure for the target ulcer

    1-12 weeks

  • Adverse events

    1-12 weeks

Study Arms (1)

Retrospective Relese

Retrospective case review to include all subjects that received Relese between May 2023 to April 2025.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Consecutive subjects receiving Relese in a real-world setting

You may qualify if:

  • Consecutive diabetic subjects that received a Relese product application during treatment between May 2023 and April 2025.

You may not qualify if:

  • Subjects not receiving an initial Relese application during treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Cypress Wound Care

Oklahoma City, Oklahoma, 73103, United States

Location

Premier Foot & Ankle

Denison, Texas, 75020, United States

Location

Premier Foot & Ankle

Frisco, Texas, 75033, United States

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 25, 2025

First Posted

October 10, 2025

Study Start

September 1, 2025

Primary Completion

November 1, 2025

Study Completion

December 1, 2025

Last Updated

October 10, 2025

Record last verified: 2025-09

Locations